Ribonuclease (3.1.4) Patents (Class 435/199)
-
Publication number: 20130177561Abstract: Hybrid nuclease molecules and methods for treating an immune-related disease or disorder in a mammal, and a pharmaceutical composition for treating an immune-related disease in a mammal.Type: ApplicationFiled: March 12, 2013Publication date: July 11, 2013Applicant: UW CENTER FOR COMMERCIALIZATIONInventor: UW CENTER FOR COMMERCIALIZATION
-
Publication number: 20130177942Abstract: The present invention relates to methods of improving the introduction of DNA into bacterial host cells.Type: ApplicationFiled: January 21, 2013Publication date: July 11, 2013Applicant: NOVOZYMES, INC.Inventor: Novozymes, Inc.
-
Patent number: 8476493Abstract: The present invention relates to the regulation of reproductive development, particularly to the genetic ablation of reproductive tissues in angiosperm and gymnosperm species. Reproductive-preferred promoters, regulatory elements, and cytotoxic nucleotide sequences are disclosed herein, as are constructs and methods for genetic ablation.Type: GrantFiled: September 23, 2011Date of Patent: July 2, 2013Assignee: Arborgen Inc.Inventors: William H. Rottmann, Kim H. Norris-Caneda, Chunsheng Zhang
-
Patent number: 8470315Abstract: The present invention is directed toward the delivery of a toxic protein to pathogenic cells, particularly cancer cells. In preferred embodiments, the toxic protein is a ribonuclease that has been modified to make it toxic to target cells and that can be conjugated to a target cell-specific delivery vector, such as an antibody, for delivery to pathogenic cells.Type: GrantFiled: April 13, 2005Date of Patent: June 25, 2013Assignee: Quintessence Biosciences, Inc.Inventors: Laura E. Strong, Peter A. Leland, Thomas Burke
-
Publication number: 20130150251Abstract: The present invention relates to compositions and methods useful for analyzing lariat RNA, which plays a role in the regulation of gene expression. A sample of RNA is specifically treated to remove linear mRNA and enrich for lariat RNA. The enriched lariat RNA sample may be analyzed further to identify introns, branch point sequences, alternative splicing patters, and gene transcription levels. The enriched lariat RNA sample may also be exploited as a detection or compound screening tool, as well as other uses.Type: ApplicationFiled: October 29, 2012Publication date: June 13, 2013Applicant: The Curators of the University of MissouriInventor: The Curators of the University of Missouri
-
Publication number: 20130149786Abstract: The present invention relates to 1-Cre1 variants which can in particular recognise and cleave DNA targets which do not comprise the same nucleotides at positions ±6 and ±7 which are present in the wild type 1-Cre1 target. The present invention also relates to 1-Cre1 variants which can recognise and cleave targets which do not comprise the wild type nucleotides at positions ±4, ±5, ±6, ±7 and to 1-Cre1 variants with new specificity which can recognise and cleave targets which do not comprise the wild type nucleotides at positions ±4, ±5, ±6, ±7, ±8, ±9 and ±10.Type: ApplicationFiled: April 30, 2010Publication date: June 13, 2013Applicant: CELLECTISInventors: Philippe Duchateau, Sylvestre Grizot
-
Publication number: 20130143275Abstract: The invention relates to methods for the detection of a specific sequence of RNA in a cell or tissue sample. The invention also relates to methods to enzymatically manipulate the RNA in a crude cell lysate in a number of applications.Type: ApplicationFiled: September 14, 2012Publication date: June 6, 2013Applicant: Applied Biosystems, LLCInventors: Brittan L. PASLOSKE, Quoc Hoang
-
Publication number: 20130137161Abstract: The invention relates to methods of altering expression of a genomic locus of interest or specifically targeting a genomic locus of interest in an animal cell, which may involve contacting the genomic locus with a non-naturally occurring or engineered composition that includes a deoxyribonucleic acid (DNA) binding polypeptide having a N-terminal capping region, a DNA binding domain comprising at least five or more Transcription activator-like effector (TALE) monomers and at least one or more half-monomers specifically ordered to target the genomic locus of interest, and a C-terminal capping region, wherein the polypeptide includes at least one or more effector domains, and wherein the polypeptide is encoded by and translated from a codon optimized nucleic acid molecule so that the polypeptide preferentially binds to the DNA of the genomic locus.Type: ApplicationFiled: December 31, 2012Publication date: May 30, 2013Applicants: MASSACHUSETTS INSTITUTE OF TECHNOLOGY, THE BROAD INSTITUTE INC.Inventors: The Broad Institute Inc., Massachusetts Institute Of Technology
-
Publication number: 20130137160Abstract: The invention relates to methods of altering expression of a genomic locus of interest or specifically targeting a genomic locus of interest in an animal cell, which may involve contacting the genomic locus with a non-naturally occurring or engineered composition that includes a deoxyribonucleic acid (DNA) binding polypeptide having a N-terminal capping region, a DNA binding domain comprising at least five or more Transcription activator-like effector (TALE) monomers and at least one or more half-monomers specifically ordered to target the genomic locus of interest, and a C-terminal capping region, wherein the polypeptide includes at least one or more effector domains, and wherein the polypeptide is encoded by and translated from a codon optimized nucleic acid molecule so that the polypeptide preferentially binds to the DNA of the genomic locus.Type: ApplicationFiled: December 31, 2012Publication date: May 30, 2013Applicants: MASSACHUSETTS INSTITUTE OF TECHNOLOGY, THE BROAD INSTITUTE INC.Inventors: The Broad Institute Inc., Massachusetts Institute of Technology
-
Publication number: 20130136727Abstract: Methods and compositions for treating neurodegenerative disorders using angiogenin and/or angiogenin variants are provided.Type: ApplicationFiled: November 3, 2010Publication date: May 30, 2013Applicant: PRESIDENT AND FELLOWS OF HARVARD COLLEGEInventors: Guo-fu Hu, Hiroko Kishikawa
-
Publication number: 20130122548Abstract: The present invention relates to an isolated mutant eubacterium comprising at least one mutation resulting in a substitution of at least one amino acid in the beta-subunit of the RNA-polymerase encoded for by the rpoB-gene providing an altered production of a product of interest when said production of a product of interest is compared to the production of the same product in an isogenic wild type strain grown at identical conditions, wherein the substitution of at least one amino acid occurs at any of positions 469, 478, 482, 485, or 487 of SEQ ID NO:2, or at the equivalent positions in any eubacterial RNA-polymererase beta-subunit family member. Another aspect of the invention relates to a process for producing at least one product of interest in a mutant eubacterium and to a use of the mutant eubacterium according to the invention for producing at least one product of interest.Type: ApplicationFiled: January 22, 2013Publication date: May 16, 2013Applicant: NOVOZYMES A/SInventor: Novozymes A/S
-
Publication number: 20130122568Abstract: Compositions and methods are provided for enzymes with altered properties that involve a systematic approach to mutagenesis and a screening assay that permits selection of the desired proteins. Embodiments of the method are particularly suited for modifying specific properties of restriction endonucleases such as star activity. The compositions includes restriction endonucleases with reduced star activity as defined by an overall fidelity index improvement factor.Type: ApplicationFiled: January 8, 2013Publication date: May 16, 2013Applicant: NEW ENGLAND BIOLABS, INC.Inventor: NEW ENGLAND BIOLABS, INC.
-
Patent number: 8440430Abstract: A modified Dicer polypeptide is provided, which modified Dicer polypeptide exhibits enhanced catalytic activity. Also provided is a method for producing small regulatory RNAs from a dsRNA, involving contacting a dsRNA with a subject modified Dicer. Small regulatory RNAs produced by a subject method find use in a variety of applications, including research and therapeutic applications.Type: GrantFiled: March 18, 2009Date of Patent: May 14, 2013Assignee: The Regents of the University of CaliforniaInventors: Jennifer Doudna, Enbo Ma, Ian J. MacRae
-
Publication number: 20130116247Abstract: Compounds which directly inhibit IRE-1? activity in vitro, prodrugs, and pharmaceutically acceptable salts there-of. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response or with regulated IRE1-dependent decay (RIDD) and can be used as single agents or in combination therapies.Type: ApplicationFiled: April 5, 2011Publication date: May 9, 2013Applicant: MANNKIND CORPORATIONInventors: Qingping Zeng, Andras Toro, John Bruce Patterson, Warren Stanfield Wade, Zoltan Zubovics, Yun Yang, Zhipeng Wu
-
Publication number: 20130115681Abstract: Compositions and methods are provided for enzymes with altered properties that involve a systematic approach to mutagenesis and a screening assay that permits selection of the desired proteins. Embodiments of the method are particularly suited for modifying specific properties of restriction endonucleases such as star activity. The compositions includes restriction endonucleases with reduced star activity as defined by an overall fidelity index improvement factor.Type: ApplicationFiled: January 8, 2013Publication date: May 9, 2013Applicant: NEW ENGLAND BIOLABS, INC.Inventor: New England Biolabs, Inc.
-
Publication number: 20130115680Abstract: Compositions and methods are provided for enzymes with altered properties that involve a systematic approach to mutagenesis and a screening assay that permits selection of the desired proteins. Embodiments of the method are particularly suited for modifying specific properties of restriction endonucleases such as star activity. The compositions includes restriction endonucleases with reduced star activity as defined by an overall fidelity index improvement factor.Type: ApplicationFiled: January 8, 2013Publication date: May 9, 2013Applicant: NEW ENGLAND BIOLABS, INC.Inventor: NEW ENGLAND BIOLABS, INC.
-
Publication number: 20130101665Abstract: Novel chimeric molecules, termed “half-antibodies”, which are capable of self-assembling to form an epitope recognition site. Using these half-antibodies or a vesicle, a viral particle, a composition or a kit thereof, for therapeutic applications, such as the prevention or treatment of cancers, genetic diseases, infectious diseases, and for in vitro diagnostic applications and detecting biological molecules. The half-antibodies include at least two chimeric molecules A and B, each has a polypeptide domain characteristic of a variable domain of a heavy chain or of a light chain of an antibody, and a nucleotide domain, the nucleotide domain of A and that of B being capable of pairing into a double stranded structure. Biologically active nucleic sequences can be grafted onto these chimeric molecules to prevent the expression of target genes in the interior of a human or non-human mammalian cell.Type: ApplicationFiled: April 8, 2011Publication date: April 25, 2013Applicant: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Nicolas Ugolin, Caroline Falck, Emilie Lefevre, Sylvie Chevillard, Carine Tisne-Vicrobeck
-
Publication number: 20130095551Abstract: A method for changing conformation of globular proteins is provided. The method controls the concentration of the globular proteins and the adsorption time of the globular proteins from the aqueous solution to the air/liquid interface, so that the main conformation of the globular proteins in a protein monolayer can be changed into ?-sheet or ?-helix. Meanwhile, the protein monolayer having the conformation of ?-sheet or ?-helix can be vertically deposited and transferred onto a substrate for various applications according to needs. The present invention can change three-dimensional structures of biological molecules and remain original functions thereof without additionally using any physical/chemical treatment to change the conformation of the globular proteins.Type: ApplicationFiled: May 24, 2012Publication date: April 18, 2013Applicant: NATIONAL CHENG KUNG UNIVERSITYInventors: Yuh-lang Lee, Ke-hsuan Wang
-
Patent number: 8420782Abstract: The present invention refers to methods for selectively recognizing a base pair in a DNA sequence by a polypeptide, to modified polypeptides which specifically recognize one or more base pairs in a DNA sequence and, to DNA which is modified so that it can be specifically recognized by a polypeptide and to uses of the polypeptide and DNA in specific DNA targeting as well as to methods of modulating expression of target genes in a cell.Type: GrantFiled: January 31, 2012Date of Patent: April 16, 2013Inventors: Ulla Bonas, Jens Boch, Sebastian Schornack, Thomas Lahaye
-
Publication number: 20130089911Abstract: Promoter regions associated with the Yarrowia lipolytica peroxisomal 2,4-dienoyl-CoA reductase (SPS19) gene are disclosed and have been found to be particularly effective for the expression of heterologous genes in yeast. These promoter regions will be useful for driving high-level expression of genes involved in the production of omega-3 and omega-6 fatty acids.Type: ApplicationFiled: April 2, 2012Publication date: April 11, 2013Applicant: E I DU PONT DE NEMOURS AND COMPANYInventors: QUINN QUN ZHU, SEUNG-PYO HONG
-
Publication number: 20130078229Abstract: The present invention is directed toward the delivery of toxic agents to pathogenic cells, particularly cancer cells. In some embodiments, the toxic agent is a human ribonuclease or similar agent that is toxic to cells.Type: ApplicationFiled: October 26, 2012Publication date: March 28, 2013Inventors: John A Kink, Laura E. Strong, Mark N. Shahan
-
Publication number: 20130071374Abstract: The present invention is directed to the discovery of a novel family of enzymes designated herein as mRNA interferases that exhibit endoribonuclease activity. The novel finding of the present inventors, therefore, presents new applications for which mRNA interferase nucleic and amino acid sequences, and compositions thereof may be used to advantage. The invention also encompasses screening methods to identify compounds/agents capable of modulating mRNA interferase activity and methods for using such compounds/agents. Also provided is a kit comprising mRNA interferase nucleic and/or amino acid sequences, mRNA interferase activity compatible buffers, and instruction materials.Type: ApplicationFiled: April 17, 2012Publication date: March 21, 2013Applicant: UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEYInventors: Masayori Inouye, Junjie Zhang, Yong Long Zhang
-
Publication number: 20130045506Abstract: The present invention relates to isolated polypeptides having cellulolytic enhancing activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.Type: ApplicationFiled: July 13, 2012Publication date: February 21, 2013Applicants: Novozymes, Inc., Novozymes A/SInventors: Lan Tang, Ye Liu, Junxin Duan, Yu Zhang, Christian Isak Jorgensen, Randall Kramer
-
Patent number: 8372619Abstract: Compositions and methods are provided for enzymes with altered properties that involve a systematic approach to mutagenesis and a screening assay that permits selection of the desired proteins. Embodiments of the method are particularly suited for modifying specific properties of restriction endonucleases such as star activity. The compositions include restriction endonucleases with reduced star activity as defined by an overall fidelity index improvement factor.Type: GrantFiled: July 14, 2008Date of Patent: February 12, 2013Assignee: New England Biolabs, Inc.Inventors: Zhenyu Zhu, Aine Blanchard, Shuang-Yong Xu, Shengxi Guan, Hua Wei, Penghua Zhang, Dapeng Sun, Siu-hong Chan
-
Publication number: 20130029400Abstract: Isolated and/or purified polypeptides and nucleic acid sequences encoding polypeptides from Alicyclobacillus acidocaldarius are provided. Further provided are methods for modulating or altering recombination inside or outside of a cell using isolated and/or purified polypeptides and/or nucleic acid sequences from Alicyclobacillus acidocaldarius.Type: ApplicationFiled: September 6, 2012Publication date: January 31, 2013Applicant: BATTELLE ENERGY ALLIANCE, LLCInventors: Brady D. Lee, Deborah T. Newby, Jeffrey A. Lacey, David N. Thompson, Vicki S. Thompson, William A. Apel, Francisco F. Roberto, David W. Reed
-
Patent number: 8361774Abstract: A protein is described that has an amino acid sequence characterized by at least 90% sequence identity with SEQ ID NO: 24, the protein being capable of recognizing a sequence consisting of 5?-GCCGAG-3? within the double-stranded DNA and cleaving the substrate predominantly at 21/19 nucleotides from the recognition site. A method is also described that utilizes the protein for creating a DNA tag for use as a unique identifier for paired end sequencing of DNA or serial analysis of gene expression.Type: GrantFiled: December 21, 2007Date of Patent: January 29, 2013Assignee: New England Biolabs, Inc.Inventor: Richard D. Morgan
-
Publication number: 20130011904Abstract: Cytotoxic variants of human ribonuclease 1 (RNase 1) identified through analysis of the interaction between RNase 1 and the human ribonuclease inhibitor (hRI) as defined by the three dimensional (3-D) atomic structure of the RNase1 hRI complex are disclosed. Also disclosed is the 3-D structure of the hRI·RNase 1 complex and methods for designing the RNase 1 variants.Type: ApplicationFiled: September 14, 2012Publication date: January 10, 2013Applicant: Wisconsin Alumni Research FoundationInventors: Ronald T. Raines, George N. Phillips, JR., R. Jeremy Johnson, Jason G. McCoy
-
Publication number: 20120331574Abstract: A monomer of an I-CreI meganuclease variant wherein said monomer when in dimeric form binds and cleaves DNA.Type: ApplicationFiled: May 31, 2012Publication date: December 27, 2012Applicant: CELLECTIS S.A.Inventors: Sylvain Arnould, Patrick Chames, Phillippe Duchateau, Jean-Charles Epinat, Emmanuel Lacroix, Frédéric Paques
-
Publication number: 20120329067Abstract: Provided herein are zinc linger nucleases having altered, arid in particular, improved catalytic activity and methods of generating such nucleases. Accordingly, there are provided methods for identifying improved catalytic activity of a ZFN by expressing a mutated zinc finger nuclease in a cell containing a reporter construct with a toxic gene, and a zinc finger nuclease cleavage site that is recognized by the ZFN. Survival of the cell is positively correlated with catalytic activity of the ZFN; thus, libraries of mutated ZFKs may be selected for altered catalytic activity based on relative survival rates, Methods of using identified ZFNs are also provided.Type: ApplicationFiled: January 21, 2011Publication date: December 27, 2012Inventors: Carlos F. Barbas III, Jing Guo
-
Publication number: 20120329709Abstract: The present invention provides methods and materials by which glycosylation of glycoproteins can be regulated. Methods include the monitoring and regulation of parameters such that a glycoprotein having a desired product quality is obtained.Type: ApplicationFiled: May 25, 2010Publication date: December 27, 2012Inventors: Brian Edward Collins, Tiffany Guo, Lakshmanan Thiruneelakantapillai, Kevin Millea, Dorota A. Bulik
-
Patent number: 8338157Abstract: The invention relates to the field of molecular biology and recombinant nucleic acid technology. In particular, the invention relates to a rationally-designed, non-naturally-occurring meganuclease with altered DNA recognition sequence specificity which recognizes and cleaves a unique DNA site in the maize genome. Disclosed herein are meganucleases which are variants of the I-CreI and LIG-34meganucleases. The invention also relates to methods of producing engineered maize plants using such meganucleases.Type: GrantFiled: September 10, 2010Date of Patent: December 25, 2012Assignee: Precision Biosciences, Inc.Inventors: Derek Jantz, James Jefferson Smith
-
Patent number: 8338185Abstract: Provided herein are methods for determining potency of RNAi agents. Such methods include, but are not limited to, cell-based and cell-free assays that measure binding of an RNAi agent with Ago2 or that measure Ago2 activity in the presence of such RNAi agents. Also provided are assays that determine potency of RNAi agents by assessing their ability to compete with other RNAi agents, including control RNAi agents, for binding and/or activation of Ago2.Type: GrantFiled: December 5, 2011Date of Patent: December 25, 2012Assignee: Isis Pharmaceuticals, Inc.Inventors: Walter F. Lima, Timothy Vickers, Stanley T. Crooke
-
Publication number: 20120324603Abstract: The invention relates to chimeric endonucleases, comprising an endonuclease and a heterologous DNA binding domain, as well as methods of targeted integration, targeted deletion or targeted mutation of polynucleotides using chimeric endonucleases.Type: ApplicationFiled: November 26, 2010Publication date: December 20, 2012Applicant: BASF Plant Sceience Company GmbHInventors: Andrea Hlubek, Christian Biesgen, Hans Wolfgang Höffken
-
Publication number: 20120322137Abstract: This invention relates to altered forms of members of the RNase A superfamily. An RNase A can be modified to be cytotoxic by altering its amino acid sequence so that it is not bound easily by the ribonuclease inhibitor while still retaining catalytic properties. While earlier work had identified some modifications to RNase A that would result in cytotoxicity, the use of the FADE algorithm for molecular interaction analysis has led to several other locations that were candidates for modification. Some of those modifications did result in RNase A variants with increase cytotoxicity.Type: ApplicationFiled: July 26, 2012Publication date: December 20, 2012Inventors: Ronald T. Raines, Julie C. Mitchell, Thomas J. Rutkoski
-
Publication number: 20120309073Abstract: The invention provides budding yeast that have a functional RNAi pathway. The invention provides RNAi pathway polypeptides derived from budding yeast that have an endogenous RNAi pathway. In some embodiments the invention provides functional budding yeast Dicer polypeptides and variants thereof. In some embodiments the invention provides functional budding yeast Argonaute polypeptides and variants thereof. Also provided are isolated nucleic acids encoding the polypeptides of the invention, vectors comprising such nucleic acids, and methods of making the polypeptides and nucleic acids. The invention further provides genetically engineered cells that comprise a functional RNAi pathway polypeptide derived from budding yeast. In some embodiments such cells lack a functional endogenous RNAi pathway and are genetically engineered to have a functional RNAi pathway by introducing nucleic acid(s) encoding one or more functional RNAi pathway polypeptides derived from budding yeast.Type: ApplicationFiled: September 10, 2010Publication date: December 6, 2012Applicants: Whitehead Institute for Biomedical Research, of Queen Elizabeth Near DublinInventors: David P. Bartel, Ines A. Drinnenberg, David E. Weinberg, Kathleen T. Xie, Kenneth H. Wolfe, Gerald Fink
-
Publication number: 20120309092Abstract: The present invention relates to plant-produced angiogenins, to related plant cells, plant calli, plants, seeds and other plant parts and products derived therefrom and to uses of plant-produced angiogenins. The present invention also relates to expression of angiogenin genes in plants and to related nucleic acids, constructs and methods.Type: ApplicationFiled: November 18, 2010Publication date: December 6, 2012Applicant: Agriculture Victoria Services Pty LtdInventors: German Spangenberg, Aidyn Mouradov, Jianghui Wang, Benjamin Graeme Cocks, Matthew Knight, Matthew McDonagh
-
Patent number: 8323941Abstract: LSD1, a homolog of nuclear amine oxidases, functions as a histone demethylase and transcriptional co-repressor. LSD1 specifically demethylates histone H3 lysine 4, which is linked to active transcription. Lysine demethylation occurs via an oxidation reaction that generates formaldehyde. Importantly, RNAi inhibition of LSD1 causes an increase in H3 lysine 4 methylation and concomitant de-repression of target genes, suggesting that LSD1 represses transcription via histone demethylation. The results thus identify a histone demethylase conserved from S. pombe to human and reveal dynamic regulation of histone methylation by both histone methylases and demethylases.Type: GrantFiled: April 5, 2010Date of Patent: December 4, 2012Assignee: President and Fellows of Harvard CollegeInventors: Yang Shi, Yujiang Shi
-
Patent number: 8318155Abstract: A nucleic acid cleaving agent having a cleaving activity specific to a desired cleavage site in a nucleic acid such as large DNA, which comprises (1) a nucleic acid cleaving moiety, and (2) at least two zinc finger proteins bound to the nucleic acid cleaving moiety, wherein at least one of the zinc finger proteins can specifically bind to a nucleotide sequence located upstream from the target cleavage site, and at least one of the remaining zinc finger proteins can specifically bind to a nucleotide sequence located downstream from the target cleavage site.Type: GrantFiled: March 7, 2007Date of Patent: November 27, 2012Assignee: Kyoto UniversityInventor: Takashi Sera
-
Patent number: 8309335Abstract: The present invention provides novel compositions, kits and methods employing RNA 5? polyphosphatases, RNA 5? monophosphatases, capping enzymes, decapping enzymes, nucleic acid pyrophosphatases and RNA ligases, as well as other enzymes, for selective 5? ligation tagging of desired classes of RNA molecules that differ with respect to particular chemical moieties on their 5? ends. The 5? tagged RNA molecules can be used for synthesis of tagged first-stand cDNA, double-stranded cDNA, and sense or antisense RNA for a variety of uses.Type: GrantFiled: February 29, 2012Date of Patent: November 13, 2012Assignee: Epicentre Technologies CorporationInventors: Jerome Jendrisak, Ramesh Vaidyanathan, Gary Dahl
-
Publication number: 20120276567Abstract: The invention relates to a Talaromyces transformant comprising one or more recombinant gene, capable of producing cellulase in the absence of cellulase inducer in a glucose medium, having a cellulase activity of 2 WSU/ml or more, in 16 times or more diluted supernatant or broth.Type: ApplicationFiled: November 4, 2010Publication date: November 1, 2012Applicant: DSM IP ASSETS B.V.Inventors: Alrik Pieter Los, Brenda Vonk, Marco Alexander Berg Van Den, Robbertus Antonius Damveld, Cornelis Maria Jacobus Sagt, Adrianus Wilhelmus Hermanus Vollebregt, Margot Elisabeth Francoise Schooneveld-Bergmans
-
Patent number: 8298801Abstract: The present invention is directed toward the delivery of toxic agents to pathogenic cells, particularly cancer cells. In some embodiments, the toxic agent is a human ribonuclease or similar agent that is toxic to cells.Type: GrantFiled: July 17, 2007Date of Patent: October 30, 2012Assignee: Quintessence Biosciences, Inc.Inventors: John A. Kink, Laura E. Strong, Mark N. Shahan
-
Publication number: 20120258518Abstract: Internal polar and ionizable groups are essential for enzymatic catalysis, proton transport, redox reactions, and many other functional properties of proteins. To engineer novel enzymes or to modify the function of existing ones, and to build switches that can be used to modify the stability of proteins in response to changes in pH, it is necessary to introduce polar or ionizable groups or to modify the properties of existing ones. However, internal polar and ionizable groups usually destabilize proteins. The disclosure provides new methods that allow the introduction of polar and ionizable groups into the interior of proteins, as well as new methods for improving the accuracy of pKa of an internal amino acid of a protein, and methods for mapping the folding free energy landscape of a protein.Type: ApplicationFiled: December 2, 2010Publication date: October 11, 2012Applicant: THE JOHNS HOPKINS UNIVERSITYInventors: Bertrand E. Garcia-Moreno, Daniel G. Isom
-
Publication number: 20120258517Abstract: The present inventors succeeded in cloning the CDT genes of C. coli and C. fetus, which were previously unknown, and in determining their sequences. In addition, the inventors also developed specific primers and primers common to the two species by comparing the CDTs of C. jejuni and C. fetus. Furthermore, the inventors demonstrated that these primers were applicable to multiplex PCR that simultaneously allows for the rapid and convenient determination of the presence of Campylobacter CDT and identification of species, and that they can also be used in PCR-RFLP-based typing.Type: ApplicationFiled: April 27, 2012Publication date: October 11, 2012Inventors: SHINJI YAMASAKI, MASAHIRO ASAKURA
-
Patent number: 8282921Abstract: The present invention relates to compositions and methods for treating conditions associated with angiogenesis. In particular the present invention relates to multi-unit complexes of tRNA synthetase fragments and uses thereof; diverse multi-unit complexes including a tRNA synthetase fragment; compositions and methods for modulating angiogenesis; polynucleotides encoding tRNA synthetase fragments and uses thereof; antibodies and epitopes specific to tRNA synthetase fragments; variants of tRNA synthetase fragments and uses thereof; methods for treating angiogenesis; methods for screening for anti-angiogenic agents; methods of modulating angiogenesis; kits for modulating angiogenesis; and business methods for modulating angiogenesis. Preferably the tRNA synthetase fragments are tryptophanyl tRNA synthetase fragments, and more preferably human tryptophanyl tRNA synthetase fragments.Type: GrantFiled: June 25, 2009Date of Patent: October 9, 2012Inventor: Paul Glidden
-
Publication number: 20120252093Abstract: Promoter regions associated with the Yarrowia lipolytica esterase/lipase (EL1) gene are disclosed and have been found to be particularly effective for the expression of heterologous genes in yeast. These promoter regions will be useful for driving high-level expression of genes involved in the production of omega-3 and omega-6 fatty acids.Type: ApplicationFiled: March 30, 2012Publication date: October 4, 2012Applicant: E I Du Pont De Nemours and CompanyInventor: Quinn Qun Zhu
-
Patent number: 8269061Abstract: Methods of selecting haploid embryos are disclosed. Methods of producing haploid embryos and non-viable diploid embryos on a plant are provided. Methods for selecting haploid embryos produced from haploid inducer maize lines are provided. Methods for producing improved maize haploid inducer lines are disclosed. Maize haploid inducer lines comprising transgenes causing ablated or abnormal diploid embryos are disclosed.Type: GrantFiled: October 3, 2011Date of Patent: September 18, 2012Assignee: E.I. du Pont de Nmeours and CompanyInventor: Mark E. Williams
-
Publication number: 20120220011Abstract: The present invention provides unstructured recombinant polymers (URPs) and proteins containing one or more of the URPs. The present invention also provides microproteins, toxins and other related proteinaceous entities, as well as genetic packages displaying these entities. The present invention also provides recombinant polypeptides including vectors encoding the subject proteinaceous entities, as well as host cells comprising the vectors. The subject compositions have a variety of utilities including a range of pharmaceutical applications.Type: ApplicationFiled: February 14, 2012Publication date: August 30, 2012Applicant: Amunix Operating Inc.Inventors: Volker Schellenberger, Willem P. Stemmer, Chia-wei Wang, Michael D. Scholle, Mikhail Popkov, Nathaniel C. Gordon, Andreas Crameri
-
Patent number: 8236543Abstract: A method of preventing, inhibiting and/or reversing cell motility, actin filament assembly or disassembly, proliferation, colonization, differentiation, accumulation and/or development of abnormal cells in a subject is disclosed. The method is effected by administering to the subject a therapeutically effective amount of a ribonuclease of the T2 family having actin binding activity.Type: GrantFiled: September 27, 2010Date of Patent: August 7, 2012Assignee: Yissum Research Development Company of the Hebrew University of JerusalemInventors: Levava Roiz, Betty Schwartz, Patricia Smirnoff, Oded Shoseyov
-
Patent number: 8236544Abstract: The present invention relates to methods of improving the introduction of DNA into bacterial host cells.Type: GrantFiled: October 1, 2010Date of Patent: August 7, 2012Assignee: Novozymes, Inc.Inventors: Michael Thomas, Michael Rey
-
Patent number: 8227231Abstract: Specified restriction endonucleases have been characterized for the first time by their amino acid and DNA sequences. These sequences and those with at least 90% identity thereto have been used as probes in sequence similarity analyses to identify sequence matches in a sequence database that corresponds to novel restriction endonucleases or isoschizomers. The sequence similarity analyses includes selecting a positive sequence match from any sequence producing an expectation value of less than or equal to e-02.Type: GrantFiled: August 3, 2006Date of Patent: July 24, 2012Assignee: New England Biolabs, Inc.Inventors: Richard D. Morgan, Richard J. Roberts